No Data
Express News | D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target
Express News | Immunic Shares Are Trading Lower. The Company Reported Phase 2 Data From Its CALLIPER Trial
Regulus RGLS Acquired by NVS; Immunic IMUX Phase 2 Data
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immunic Drops After Mid-stage Trial Data for Multiple Sclerosis Drug
Immunic Reports Data From Phase 2 CALLIPER Trial Of Nurr1 Activator, Vidofludimus Calcium, In Patients With Progressive Multiple Sclerosis